-
03:45:58 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

INCY Stock News

10/02/21 5:15 AM
Nasdaq : INCY
clinical trial
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
Incyte today announced the full 24- week results from its pivotal Phase 3 TRuE-V clinical trial program investigating ruxolitinib cream, a topical JAK inhibitor, in adolescent and adult patients with nonsegmental vitiligo. These data will be presented today as a late-breaking oral presentation at the European Academy of Dermatology and Venereology 30 th...
RHEA-AI
positive
09/22/21 12:38 PM
Nasdaq : INCY
fda approval
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte today announced that the U.S. Food and Drug Administration has approved Jakafi ® for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. “GVHD is the leading cause of morbidity and mortality in patients following an allogeneic stem cell transplant,...
RHEA-AI
positive
09/21/21 4:13 PM
Nasdaq : INCY
fda approval
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
Incyte today announced that the U.S. Food and Drug Administration has approved Opzelura™ cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies...
RHEA-AI
neutral
09/14/21 9:00 AM
Nasdaq : INCY
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte has been expanded to include discovery of additional novel peptide therapies. “Nimble looks forward to building upon on the already strong collaboration between the...
RHEA-AI
very positive
09/13/21 4:30 PM
Nasdaq : INCY
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Incyte today announced that multiple abstracts highlighting data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with vitiligo and atopic dermatitis will be presented at the upcoming European Academy of Dermatology and Venereology 30th Anniversary Congress, held virtually from September 29- October 2, 2021.
RHEA-AI
neutral
08/26/21 4:01 PM
Nasdaq : INCY, MOR
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Incyte and MorphoSys AG today announced that the European Commission has granted conditional marketing authorization for Minjuvi ® in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not...
RHEA-AI
neutral